Obeticholic acid (OCA) is a semisynthetic farnesoid X receptor (FXR) agonist, an analogue of chenodeoxycholic acid (CDCA) which is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). OCA efficiently inhibits bile acid synthesis and promotes bile acid efflux via activating FXRmediated mechanisms in a physiologically relevant in vitro cell system, Sandwich-cul- occurs at the C-7 hydroxyl group.
Endogenous bile acids are also signaling molecules for bile acid homeostasis. 7 Bile acids directly activate nuclear receptors including the farnesoid X receptor (FXR; NR1H4), [8] [9] [10] and the pregnane X receptor (PXR; NR1I2). 11, 12 Although bile acids share the same C 24 steroid backbone, they differentiate from each other in potency and selectivity of nuclear receptors. For example, CDCA is the most potent activator of FXR among natural bile acids 8, 9, 13 with an EC 50 value of approximately 10 lmol/L.
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Farnesoid X receptor is a key regulator of bile acid homeostasis. 7 Obeticholic acid (OCA) is an analog of CDCA that differs in structure by a single ethyl group at C 6. 14 FXR activation by OCA has an EC 50 value of approximately 100 nmol/L. 14 Previous studies by the authors utilizing a physiologically relevant cellular model of sandwich-cultured human hepatocytes (SCHH) demonstrated a significant reduction in endogenous bile acids following 72-hour incubation of OCA. 15 In the same study, a head-to-head comparison confirmed that OCA was 100-fold more potent than CDCA on FXR. In a Phase 3 clinical trial 16 , patients with primary biliary cholangitis (PBC), treated with OCA once daily, consistently had significant reductions in plasma bile acid levels compared to placebo controls.
Ursodeoxycholic acid is an epimer of CDCA, but UDCA was reported to be a weak FXR agonist 17 or did not activate FXR in in vitro models. 13, 18, 19 An in vivo study 20 reported that UDCA exerted FXR-antagonistic effects in nonalcoholic fatty liver disease (NAFLD) patients by demonstrating induction of hepatic CYP7A1, elevation of circulating 7a-hydroxy-4-cholesten-3-one (C4) and reduction in fibroblast growth factor . Controversially, there are no published studies showing UDCA is a direct antagonist 21 with the exception of one in silico FXR binding study showing an inhibitory effect of UDCA. 22 Ursodeoxycholic acid is the frontline treatment for many cholestatic liver diseases including PBC. 23 Its beneficial effects in cholestasis have been studied over decades. Multiple mechanisms of action have been proposed for its effects in the liver and intestine. 24, 25 Beneficial effects of UDCA could be attributed to its hydrophilic properties. Recently, OCA was approved for the treatment of PBC in patients who were intolerant to UDCA or who had an inadequate response to UDCA. The concomitant use of UDCA and OCA in PBC therapy demands an understanding of the pharmacological interactions between UDCA and OCA.
Bile acid synthesis occurs and is regulated in the liver. The hepatic regulation pathway mediated by OCA has been clarified previously in SCHH. 15 
| RT-PCR quantitation of mRNA expression
Total RNA was isolated from human hepatocytes and Caco-2 cells after treatment using Qiagen RNeasy kit following manufacturer's instructions. Isolated RNA was quantified using Quant-iT TM RiboGreen â RNA Assay Kit (Thermo Fisher Scientific, Carlsbad, CA).
Total RNA was pooled together from triplicate wells, and a total amount of 500 ng was converted to cDNA following the manufacturer's procedure of the High Capacity cDNA Archive Kit (Thermo Fisher Scientific). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. mRNA content was determined for each treatment group relative to the endogenous control gene expression and the calibrator, 0.1% vehicle control (DMSO) using the ViiA TM 7 system software (Thermo Fisher Scientific, Carlsbad, CA).
| Bioanalysis of endogenous bile acid pool (EBAP)
EBAP in SCHH was analyzed using B-CLEAR â technology and calculated as the sum of endogenous primary bile acids (CA and CDCA)
and their glycine and taurine conjugates (glyco-CA, tauro-CA, glyco-CDCA, and tauro-CDCA) in cell culture medium, and hepatocyte lysate (cell + bile). Endogenous bile acids were extracted from cell culture medium samples and hepatocyte lysate using the same procedure described in the previous paper. 15 Prepared samples were filtered and analyzed by LC-MS/MS using a Shimadzu binary HPLC system (Columbia, MD) and tandem mass spectrometry using 
| Data analysis
Data were analyzed with GraphPad Prism 7.02 (GraphPad Software, Inc., La Jolla, CA). All data are normalized to the vehicle control (DMSO). For hepatocyte studies, mean and standard deviation (SD)
were calculated from hepatocyte preparations of three liver donors.
For the gene expression from Caco-2 cell study, mean and 95% confidence intervals (CI) were calculated from technical triplicate. mRNA ( Figure 5A ). UDCA (≤100 lmol/L) mono-treatment showed no effect on CYP3A4 mRNA levels, but UDCA at 316 lmol/L increased CYP3A4 mRNA 15.4 AE 9.8-fold relative to the control ( Figure 5B ). In the cotreatment assays, UDCA at 316 lmol/L abolished the suppression of CYP3A4 mRNA levels by OCA; instead, a 10.5 AE 2.7-fold increase in CYP3A4 mRNA was observed relative to the control ( Figure 5C ). This result confirmed that in SCHH, UDCA at 316 lmol/L is capable to activate PXR.
| FXR activation in human Caco-2 cells
In 37 while rat ASBT is not. 38 There is significant species difference in regulation of the ASBT gene by bile acids. 27, 37, 38 The mechanisms of ASBT regulation in human enterocytes by bile acids require further investigation.
Our studies also demonstrated that UDCA may be a weak PXR agonist. UDCA at 316 lmol/L induced the expression of CYP3A4, a prototypical PXR target gene. 38 Previous reports show that PXR activation induces FGF-19 expression. 39 We observed that high concentration of UDCA (316 lmol/L) increased FGF-19 mRNA, which may be why high concentrations of UDCA were found to decrease the expression of CYP7A1 and the total endogenous bile acid pool. A limitation of this study was that only endogenous cholic acid was used for efficacy measurement when UDCA was administered with OCA. For mono-treatments, the level of the total endogenous bile acids represents the activity of bile acid synthesis. Total endogenous bile acids were calculated as the sum of CA, glyco-CA, tauro-CA, CDCA, glyco-CDCA, and tauro-CDCA. But we observed that, in the cotreatment of UDCA and OCA assays, total CDCA (the sum of CDCA, glyco-CDCA, and tauro-CDCA), marker for OCA effects was increased with the increasing concentrations of UDCA. This may be due to the epimerization of UDCA to CDCA. Instead of total endogenous bile acids, only total cholic acid was calculated as the sum of CA, glyco-CA, and tauro-CA, and used as the representative of the activity of bile acid synthesis in this SCHH system. This is reasonable because cholic acid is synthesized from the classic pathway in which CYP7A1 is the rate-limiting enzyme. 7 In summary, this study demonstrated that UDCA is not a FXR agonist. Co-administration of UDCA with OCA did not affect the ability of OCA to activate FXR and thus suppress bile acid synthesis.
